

QUERY CONTROL FORM

RTIS USE ONLY

Application No. 09777526
Examiner-GAU Lc Guyader
1635

Prepared by ewc
Date 8/20/04
No. of queries - 1 -

Tracking Number 05998405
Week Date 8-09-04
IFW

JACKET

a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION

- Page Missing
- Text Continuity
- Holes through Data
- Other Missing Text
- Illegible Text
- Duplicate Text
- Brief Description
- Sequence Listing
- Appendix
- Amendments
- Other

CLAIMS

- a. Claim(s) Missing
- b. Improper Dependency
- c. Duplicate Numbers
- d. Incorrect Numbering
- e. Index Disagrees
- f. Punctuation
- g. Amendments
- h. Bracketing
- i. Missing Text
- j. Duplicate Text
- k. Other


MESSAGE

MESSAGE PTO - 1449
Please either initial or line
through citations - See attached copies
Thank you
CWC

RESPONSE

initials

initials



Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Sheet

1

OF

4

Docket Number
HYZ-030CPCN3Application Number
09/777,526Applicant
Agrawal et al.Filing Date
February 6, 2001Group Art Unit
1635

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,309,404	1/5/1982	DeNeale et al.	424	21	
	4,309,406	1/5/1982	Guley et al.	424	21	
	4,556,552	12/3/1985	Porter et al.	424	32	
	4,704,295	11/3/1987	Porter et al.	427	3	
	5,220,007	6/15/1993	Pederson et al.	536	23.1	
	5,149,797	9/22/1992	Pederson et al.	536	23.1	
	5,220,007	12/21/1993	Cho-Chung	424	450	
	5,248,670	9/28/1993	Draper et al.	514	44	
	5,271,941	12/21/1993	Cho-Chung	424	450	
	5,403,709	10/6/1992	Agrawal et al.	435	6	
	5,442,049	8/15/1995	Anderson et al.	536	24.5	
	5,470,967	11/28/1995	Huie et al.	536	24.3	
	5,514,577	5/7/1996	Draper et al.	435	238	
	5,578,716	12/1/1993	Szyf et al.	536	24.5	
	5,612,212	11/12/1993	Gewirtz	435	456	
	6,143,881	11/7/2000	Metelev et al.	536	24.5	
	5,652,355	7/29/1997	Metelev et al.	536	24.5	
	5,969,117	10/19/1999	Agrawal	536	22.1	

RECEIVED

MAY 23 2001

TECH CENTER 1600/2900

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	94/02498	2/3/1994	WO	C07H 21	00		X
	94/15619	7/21/1994	WO	A61K 31	70		X

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

A1	Agrawal, Sudhir, "Functionalization of oligonucleotides with amino groups and attachment of amino specific reporter groups." <i>Methods Mol Biol.</i> , Vol. 26, pp. 93-120 (1994)
A2	Agrawal et al., "Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues." <i>Proc Natl Acad Sci U S A.</i> , Vol. 86, No. 20, pp. 7790-4 (1989)
A3	Agrawal, <u>Antisense Therapeutics</u> , (Sudhir Agrawal, ed.), Page V (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subl. For, PTO-1449		Docket Number HYZ-030CPCN3	Application Number 09/777,526
INFORMATION DISCLOSURE IN AN APPLICATION MAY 21 2001 (Use several sheets if necessary)		Applicant Agrawal et al.	
		Filing Date February 6, 2001	Group 1635
3	OF	4	

RECEIVED

MAY 23 2001

TECH CENTER 1600/2000

B17	Inoue et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H." <i>FEBS Lett.</i> , Vol. 215, No. 2, pp. 327-30 (1987)
B18	Inoue et al., <i>FEBS Lett.</i> , Vol. 215, pp. 237-250 (1987)
B19	Iversen, "In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue." <i>Anticancer Drug Des.</i> , Vol. 6, No. 6, pp. 531-8 (1991)
C1	Iversen, "Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion." <i>Antisense Res Dev.</i> , Vol. 4, No. 1, pp. 43-52 (1994)
C2	Kawasaki et al., "Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets." <i>J Med Chem.</i> , Vol. 36, No. 7, pp. 831-41 (1993)
C3	Levin (10/8-9/98) <i>Antisense 98, Targeting the Molecular Basis of Disease</i> , pp. 25
C4	Martin, P. <i>Helvetica Chimica Acta</i> , 78: 486-504 (1995)
C5	Meteliev et al, <i>Bioorganic & Medicinal Chemistry Letters</i> , 4: 2929-2934 (1994)
C6	Milligan et al., "Current concepts in antisense drug design." <i>J Med Chem.</i> , Vol. 36, No. 14, pp. 1923-37 (1993)
C7	Orr, (Reported By) <i>Antisense 98: "Targeting the Molecular Basis of Disease (Part III)" Organized by Nature Biology, London, UK (1988)</i>
C8	Quartin et al., "Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates." <i>Nucleic Acids Res.</i> , Vol. 17, No. 18, pp. 7253-62 (1989)
C9	Rapaport et al., "Antimalarial activities of oligodeoxynucleotide phosphorothioates in chloroquine-resistant <i>Plasmodium falciparum</i> ." <i>Proc Natl Acad Sci U S A.</i> , Vol. 89, No. 18, pp. 8577-80 (1992)
C10	Sands, "Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate." <i>Mol Pharmacol.</i> , Vol. 45, No. 5, pp. 932-43 (1994)
C11	Shibahara et al., "Site-directed cleavage of RNA." <i>Nucleic Acids Res.</i> , Vol. 15, No. 11, pp. 4403-15 (1987)
C12	Shibahara et al., "Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives." <i>Nucleic Acids Res.</i> , Vol. 17, No. 1, pp. 239-52 (1989)
C13	Shibahara et al., <i>Nucleic Acids Res.</i> , Vol. 15, pp. 4403-4415 (1987)
C14	Sonveaux, "Protecting Groups in Oligonucleotide Synthesis", in <i>Methods in Molecular Biology</i> (Agrawal ed.) 26:1-71 (1994)
C15	Stein et al., "Antisense oligonucleotides as therapeutic agents--is the bullet really magical?" <i>Science</i> , Vol. 261, No. 5124, pp. 1004-12 (1993)
C16	Takashima et al., "Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity." <i>Proc Natl Acad Sci U S A.</i> , Vol. 90, No. 16, pp. 7789-93 (1993)
C17	Tidd et al., "Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups." <i>Br J Cancer.</i> , Vol. 60, No. 3, pp. 343-50 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYZ-030CPCN3Application Number
09/777,526Applicant
Agrawal et al.Filing Date
February 6, 2001Group Art Unit
1635

Sheet: 4 OF 4

C18	Tortora et al., "Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production." <i>Clin Cancer Res.</i> Vol. 6, No. 6, pp. 2506-12 (2000)
C19	Tseng et al., "Antisense oligonucleotide technology in the development of cancer therapeutics." <i>Cancer Gene Ther.</i> ; Vol. 1, pp. 65-71 (1994)
C20	Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle" <i>Chem. Rev.</i> Vol. 90, pp. 543-584 (1990)
D1	Wang et al., "Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the R1alpha subunit of protein kinase A after oral administration." <i>Proc Natl Acad Sci U S A.</i> , Vol. 96, No. 24, pp. 13989-94 (1999)
D2	Wickstrom, E., "Oligodeoxynucleotide stability in subcellular extracts and culture media." <i>J Biochem Biophys Methods.</i> , Vol. 13, No. 2, pp. 97-102. (1986)
D3	Wickstrom, E., "Strategies for administering targeted therapeutic oligodeoxynucleotides." <i>Trends Biotechnol.</i> , Vol. 10, No. 8, pp. 281-7(1992)
D4	Zamecnik, P., "History of Antisense Oligonucleotides" in Antisense Therapeutics (Sudhir Agrawal ed.), Human Press, Totowa, New Jersey (1996) pp. 1-11.
D5	Zhao et al., <i>Antisense Res. and Dev.</i> 3: 53-66 (1993)
D6	Zon, <i>Pharm. Res</i> 5(9): 539-49 (1988)
D7	Zendegui et al., "In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides." <i>Nucleic Acids Res.</i> , Vol. 20, No. 2, pp. 307-14 (1992)

RECEIVED
MAY 23 2001
TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	